Canton Biologics
Latest round
- Series C
Last raised
- Sep 2023
Total raised
- $41M
Investors
- 4
About Canton Biologics
Established in 2016 and based in Guangzhou, China, Canton Biologics operates as a biomolecule drug CDMO company that provides biomolecule drug development and manufacturing services, including monoclonal antibodies, duplex antibodies, fusion proteins and recombinant proteins. The company is headquartered in Guangzhou, and has R&D centers in Guangzhou and Germany as well as production centers in Foshan. It has a 12000m² commercialized production base and many awards, such as "National High-tech Enterprise" and Guangdong Province's "Pearl River Talent Program" innovation and entrepreneurship team. In February 2022, it acquired a Germany company - FyoniBio GmbH. In June 2023, the company was selected as one of “the Top 10 Most Growing CDMO Companies”. The company provides CMC development services, GMP manufacturing services and management systems services. CMC development services include molecular design, optimization and developmental assessment, cell line development and library construction, and upstream and downstream process development. GMP manufacturing services include toxicology, batch approval and clinical sample production, commercial production, quality control and test release, and aseptic filling. Management systems include project management, GMP manufacturing management, intellectual property management and drug registration management. In addition, it has related technology platforms, including cell line development platforms, process development platforms and analytical methods development platforms.
Who invested in Canton Biologics
4 investors across 1 round
See all investors in Canton Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Sep 13, 2023
Amount
$41M
Investors
Questions about Canton Biologics
Who invested in Canton Biologics?
Canton Biologics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Canton Biologics raised?
Canton Biologics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Canton Biologics last raise money?
Canton Biologics's most recent round on record is a Series C, in Sep 2023.
What does Canton Biologics do?
Established in 2016 and based in Guangzhou, China, Canton Biologics operates as a biomolecule drug CDMO company that provides biomolecule drug development and manufacturing services, including monoclonal antibodies, duplex antibodies, fusion proteins and recombinant proteins.
Where is Canton Biologics headquartered?
Canton Biologics is headquartered in Guangzhou, China.
Which VCs invest in companies like Canton Biologics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back outsourcing companies at Canton Biologics's stage. Their profiles are linked below.
VCs backing outsourcing startups at Series C
Raising like Canton Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.